Claus Frisenberg buys shares in Oncology Venture and MPI
Hoersholm, Denmark – March 27th 2018 Oncology Venture Sweden AB (OV:ST) (“Oncology Venture”) and Medical Prognosis Institute (MPI.ST) (“MPI”) announces that Claus Frisenberg, CCO and CFO in Oncology Venture, has bought 3 700 shares in Oncology Venture at a price of 18,36 SEK per share and 6 300 shares in MPI at a price of 10,816 SEK per share. All shares has been bought on March 26, 2018, in the trade at AktieTorget and Nasdaq Stockholm First North, respectively. On 9th March 2018 Oncology Venture and Medical Prognosis Institute announced plans of a merger of the companies.